JP2005509596A5 - - Google Patents

Download PDF

Info

Publication number
JP2005509596A5
JP2005509596A5 JP2003518484A JP2003518484A JP2005509596A5 JP 2005509596 A5 JP2005509596 A5 JP 2005509596A5 JP 2003518484 A JP2003518484 A JP 2003518484A JP 2003518484 A JP2003518484 A JP 2003518484A JP 2005509596 A5 JP2005509596 A5 JP 2005509596A5
Authority
JP
Japan
Prior art keywords
nanoparticle
nanoparticles
fibrate
oil
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003518484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005509596A6 (ja
JP2005509596A (ja
JP4721640B2 (ja
Filing date
Publication date
Priority claimed from GBGB0119480.2A external-priority patent/GB0119480D0/en
Application filed filed Critical
Publication of JP2005509596A publication Critical patent/JP2005509596A/ja
Publication of JP2005509596A6 publication Critical patent/JP2005509596A6/ja
Publication of JP2005509596A5 publication Critical patent/JP2005509596A5/ja
Application granted granted Critical
Publication of JP4721640B2 publication Critical patent/JP4721640B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003518484A 2001-08-09 2002-08-09 フェノフィブラートのナノ粒子製剤 Expired - Fee Related JP4721640B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0119480.2 2001-08-09
GBGB0119480.2A GB0119480D0 (en) 2001-08-09 2001-08-09 Novel compositions
PCT/GB2002/003687 WO2003013474A1 (en) 2001-08-09 2002-08-09 Nanoparticulate formulations of fenofibrate

Publications (4)

Publication Number Publication Date
JP2005509596A JP2005509596A (ja) 2005-04-14
JP2005509596A6 JP2005509596A6 (ja) 2005-08-04
JP2005509596A5 true JP2005509596A5 (https=) 2006-01-05
JP4721640B2 JP4721640B2 (ja) 2011-07-13

Family

ID=9920132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003518484A Expired - Fee Related JP4721640B2 (ja) 2001-08-09 2002-08-09 フェノフィブラートのナノ粒子製剤

Country Status (8)

Country Link
US (1) US8663693B2 (https=)
EP (1) EP1414410B1 (https=)
JP (1) JP4721640B2 (https=)
AT (1) ATE422155T1 (https=)
DE (1) DE60231082D1 (https=)
ES (1) ES2321912T3 (https=)
GB (1) GB0119480D0 (https=)
WO (1) WO2003013474A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
AU2003245313A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
CN1829499A (zh) * 2003-05-29 2006-09-06 格利康科技集团有限责任公司 稳定并控制传递(－)－羟基柠檬酸的方法和组合物
JP2008514714A (ja) * 2004-09-30 2008-05-08 イーストマン ケミカル カンパニー 有意な流出阻害を示さない、親油性薬物を可溶化するビタミンｅｔｐｇｓ分子を含む医薬製剤及びこのような医薬製剤の使用
JP5112669B2 (ja) * 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
US20070128289A1 (en) * 2005-12-07 2007-06-07 Zhao Jonathon Z Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases
WO2008002568A2 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US20080161594A1 (en) * 2006-12-29 2008-07-03 Industrial Technology Research Institute Method for fabricating nanoparticles containing fenofibrate
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
JP5711671B2 (ja) 2009-02-23 2015-05-07 ナノルクス、インコーポレイテッドＮａｎｏｒｘ，Ｉｎｃ． ポリコサノールナノ粒子
US8888736B2 (en) 2010-04-30 2014-11-18 H R D Corporation High shear application in medical therapy
WO2011139479A2 (en) 2010-04-30 2011-11-10 H R D Corporation High shear application in drug delivery
CA2844073C (en) 2010-08-23 2015-10-13 NanoRx, Inc. Policosanol nanoparticles
GB201118181D0 (en) * 2011-10-21 2011-12-07 Jagotec Ag Pharmaceutical compositions
BR112015001838B1 (pt) * 2012-07-27 2022-10-25 Izumi Technology, Llc Composição de inibidor de efluxo
CN104903494B (zh) * 2012-09-21 2017-11-03 瑞奥可塞恩探索集团有限公司 用于电解液体的电池
US11285115B2 (en) 2013-02-28 2022-03-29 Ramot At Tel-Aviv University Ltd. Peptide-based hydrogel particles and uses thereof
CN105218370A (zh) * 2014-06-10 2016-01-06 无锡康福特药物科技有限公司 一种贝特类降脂药物的超微粉体及其制备方法
PL3833335T3 (pl) * 2019-07-31 2023-01-02 Intas Pharmaceuticals Ltd. Kompozycja farmaceutyczna zawierająca inhibitory reduktazy HMG-CoA i fenofibrat
PL3928772T3 (pl) 2020-06-26 2024-10-07 Algiax Pharmaceuticals Gmbh Kompozycja nanocząstkowa
US20230398234A1 (en) * 2020-10-28 2023-12-14 Mydecine Innovations Group Inc. Novel fungal compoind formulations and their therapeutic methods of use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
DE19800250A1 (de) 1997-01-13 1998-08-06 Winter Cvd Technik Gmbh Schleifkörper
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
WO1999029300A1 (en) * 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FR2776191B1 (fr) 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
CA2335472C (en) 1998-06-19 2008-10-28 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
FR2783421B1 (fr) 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
EP1133280A1 (en) 1998-11-20 2001-09-19 RTP Pharma Inc. Method of preparing stable suspensions of insoluble microparticles
US6180138B1 (en) * 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2795961B1 (fr) 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US6251426B1 (en) * 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
ATE296091T1 (de) * 1999-09-21 2005-06-15 Skyepharma Canada Inc Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US6464511B1 (en) 1999-11-17 2002-10-15 Advantest Corporation IC socket and IC tester
FR2803203B1 (fr) 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate

Similar Documents

Publication Publication Date Title
JP2005509596A5 (https=)
Khalil et al. Biosynthesis of Au nanoparticles using olive leaf extract: 1st nano updates
ATE422155T1 (de) Nanopartikelzusammensetzungen enthaltend fenofibrat
Basavegowda et al. Preparation of Au and Ag nanoparticles using Artemisia annua and their in vitro antibacterial and tyrosinase inhibitory activities
Tom et al. Ciprofloxacin-protected gold nanoparticles
PL1957041T3 (pl) Emulsja olej-w-wodzie i jej zastosowanie dla nadania funkcji
Rameshkumar et al. In vitro antioxidant and antimicrobial activities of Merremia emarginata using thio glycolic acid-capped cadmium telluride quantum dots
EP1582194A4 (en) COSMETIC COMPOSITION
Reijnders Human health hazards of persistent inorganic and carbon nanoparticles
DE69915733D1 (de) Kosmetische oder pharmazeutische Zusammensetzung in Form eines Feststoffs, welche verformt werden kann
WO2005120173A3 (en) Anti-microbial activity of biologically stabilized silver nano particles
AR022974A1 (es) Una preparacion de cilostazol y un proceso para mejorar la absorcion de una droga levemente soluble.
DE60315437D1 (de) Nanoskaliges zinkoxid, herstellungs- und verwendungsverfahren
Pattanayak et al. Green synthesis of gold nanoparticles using Elettaria cardamomum (ELAICHI) aqueous extract
MX2011009651A (es) Formulacion que comprende particulas de avermectina revestidas con agente fotoprotector.
Mehn et al. Immobilised gold nanostars in a paper-based test system for surface-enhanced Raman spectroscopy
JP2004327432A5 (https=)
RU2445951C1 (ru) Способ получения концентратов нанодисперсий нульвалентных металлов с антисептическими свойствами
JP2004534074A5 (https=)
Sagadevan et al. Facile fabrication of Au-loaded CdO nanoconstructs with tuned properties for photocatalytic and biomedical applications
CN110605135A (zh) 可见光响应的二氧化钛/石墨相复合光触媒水溶胶及其制备方法
WO2007057182A3 (de) Fluoreszenz-nanopartikel
DE602005012761D1 (de) Topische Zusammensetzung enthaltend poröse Partikel und eine Sebum absorbierende Verbindung
WO2003049710A3 (de) Lippenstift
Barbinta-Patrascu et al. Photophysical studies on biocomposites based on carbon nanotubes and chlorophyll-loaded biomimetic membranes